Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV

PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Philadelphia, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, was interviewed on CEOLIVE.TV on November 13, 2017.

The interview can be viewed at:

Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market

About CEOLIVE.TV
CEOLIVE.TV is an online investor media and news resource featuring interviews and commentary with top executives from U.S. publicly traded companies.

About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.

Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Any forward-looking statements set forth in this press release speak only as of the date of this press release.  We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contact
Phone Number: 800-778-4042
Email: IR@hemispherx.net 

Ads